Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Operating Leases (2021 - 2026)

Zentalis Pharmaceuticals has reported Operating Leases over the past 6 years, most recently at $34.6 million for Q1 2026.

  • For Q1 2026, Operating Leases fell 10.35% year-over-year to $34.6 million; the TTM value through Mar 2026 reached $34.6 million, down 10.35%, while the annual FY2025 figure was $35.7 million, 9.79% down from the prior year.
  • Operating Leases for Q1 2026 was $34.6 million at Zentalis Pharmaceuticals, down from $35.7 million in the prior quarter.
  • Over five years, Operating Leases peaked at $46.4 million in Q2 2023 and troughed at $34.6 million in Q1 2026.
  • A 5-year average of $41.1 million and a median of $40.9 million in 2024 define the central range for Operating Leases.
  • Biggest five-year swings in Operating Leases: grew 1.59% in 2022 and later fell 14.78% in 2025.
  • Year by year, Operating Leases stood at $45.2 million in 2022, then decreased by 4.46% to $43.2 million in 2023, then dropped by 8.28% to $39.6 million in 2024, then decreased by 9.79% to $35.7 million in 2025, then dropped by 2.95% to $34.6 million in 2026.
  • Business Quant data shows Operating Leases for ZNTL at $34.6 million in Q1 2026, $35.7 million in Q4 2025, and $36.7 million in Q3 2025.